This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Dexcom (DXCM) Gets a Buy from BTIG

Tipranks - Tipranks - Fri Jun 19, 8:15AM CDT

BTIG analyst Marie Thibault maintained a Buy rating on Dexcom on June 15 and set a price target of $80.00. The company’s shares closed yesterday at $74.22.

Claim 55% Off TipRanks

According to TipRanks, Thibault is an analyst with an average return of -14.3% and a 33.40% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Insulet, and Dexcom.

Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $83.47, a 12.46% upside from current levels. In a report released on June 15, Piper Sandler also maintained a Buy rating on the stock with a $88.00 price target.

See the top stocks recommended by analysts >>

Based on Dexcom’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.19 billion and a net profit of $199.5 million. In comparison, last year the company earned a revenue of $1.04 billion and had a net profit of $105.4 million

Read More on DXCM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).